Chemotherapy-Induced Nausea and Vomiting (CINV) Flashcards

1
Q

CINV occurs most commonly with which drugs

A

CISPLATIN**
Carboplatin
Cyclophosphamide
Anthracyclines (doxorubicin/ daunorubicin)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

CINV risk factors

A
  1. female sex
  2. younger age
  3. pretreatment anxiety
  4. Hx of motion sickness or morning sickness during pregnancy
  5. Hx of N/V with previous chemo cycles
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

CINV can be classified as:

A
  1. Acute*
  2. Delayed*
  3. Anticipatory*
  4. Breakthrough*
  5. refractory
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Acute CINV definition

A

Acute: occurs WITHIN 24H after chemo and peaks around 5-6H

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Delayed CINV definition

A

Delayed: occurs > 24H after chemo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Anticipatory CINV definition

A

Anticipatory: occurs BEFORE TREATMENT and develops as a CONDITIONED RESPONSE from a previous negative experience

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Breakthrough CINV definition

A

Breakthrough: occurs at ANY TIME after chemo, despite the use of prophylaxis, and requires rescue antiemetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

refractory CINV def

A

refractory: occurs when prohylaxis and/or rescue treatment is not effective

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

List Neurokinin-1 Receptor Antagonists (NK1 RAs)

A

Aprepitant

Fosaprepitant

Rolapitant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

List Serotonin Receptor Antagonists (5HT3 RAs)

A

Ondansetron

Dolasetron

Granisetron

Palonosetron (combo products available)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

List Dopamine Receptor Antagonists

A

Olanzapine

Haloperidol

Metoclopromide

Prochlorperazine

Promethazine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Other CINV agents

A

Dexamethasone

Lorazepam

Dronabinol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

when should antiemetic regimens be given

A

(one dose of each drug) at least 30 min before chemotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

when can Lorazepam be added to the antiemetic regimens

A

if needed for ANTICIPATORY N/V- start the night before treatment and repeated the day of treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

List the major neurotransmitters responsible for CINV

A
  1. Serotonin
  2. Dopamine
  3. GABA
  4. Substance P
  5. Neurokinin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

IV Chemotherapy Risk for Acute/Delayed N/V

*HIGH EMETIC RISK: 90% frequency of acute emesis

note: CISPLATIN, any regimen containing BOTH an anthracycline and cyclophosphamide)**

Q: Antiemetic Regimen

A
  • 3 or 4 Drugs *

*** PREFERRED: (NK1 RA) + (5HT3 RA) + (Olanzapine) + (Dexamethasone)

  • (NK1 RA) + (5HT3 RA) + (dexamethasone)
  • (Palonosetron) + (olanzapine) + (dexamethasone)
17
Q

IV Chemotherapy Risk Acute/Delayed N/V:

Moderate emetic risk: 30-90% frequency

Q: Antiemetic regimen

A
  • 2 or 3 drugs *
  1. (NK1 RA) + (5HT3 RA) + (dexamethasone)
  2. (5HT3 RA) + (dexamethasone)
  3. (Palonosetron) + (olanzapine) + (dexamethasone)
18
Q

IV Chemotherapy Risk for Acute/Delayed N/V:

Low emetic risk: 10 -30%

Q: Antiemetic regimen

A
  • 1 Drug *
  1. 5HT3 RA (think “dog” ; dolasetron, ondansetron, granisetron)
  2. dexamethasone
  3. metoclopramide
  4. prochlorperazine
19
Q

IV Chemotherapy Risk:

Minimal emetic risk: < 10%; the majority of mAbs

Q: Antiemetic regimen

A

NO ROUTINE PROPHYLAXIS

20
Q

MOA: Substance P/ NK1 RA:
inhibits the sub P/NK1 receptor, thereby augmenting the antiemetic activity of 5HT3 receptor antagonists and corticosteroids

Q: List drugs

A
  1. Aprepitant (EMEND, emend Tri-Pack, Cinvanti)*
  2. Fosaprepitant (EMEND)*
  3. Rolapitant (Varubi)
21
Q

which subtance P/NK1 drug is given IV

A

fosaprepitant (Emend)

note: aprepitant (Cinvanti is also IV, all others are PO)

22
Q

fosaprepitant IV is converted to aprepitant within how many minutes after the end of the infusion

A

within 30 min after the end of the infusion

23
Q

which drugs inhibit the metabolism of dexamethasone (to INCREASE dexamethasone levels)

A

aprepitant, fosaprepitant and netupitant (combo drug w/palonosetron)

24
Q

which drug do you NOT administer at less than 2-week intervals

A

rolapitant

25
Q

5HT3 RA drugs

A
  1. Ondansetron (Zofran)*
  2. Granisetron (Sancuso)*
  3. Palonosetron (Aloxi)*
  4. Dolasetron (Anzemet)
26
Q

Q: which 5HT3 RA is available in PO, IV, SC, and PATCH*

Q: Patch directions

A
  1. granisetron (Sancuso is patch formulation)*
  2. 3.1 mg/24 H, apply 24-48H before chemo; may leave in place up to 7 DAYS
27
Q

side effects of 5HT3 RAs

A

HA, CONSTIPATION*, fatigue, dizziness, injection site rxn

28
Q

Contraindication of 5HT3 RAs

A

do NOT use with APOMORPHINE (Apokyn)* due to severe hypOtension

29
Q

Warnings with 5HT3 RAs

A
  1. dose- dependent QT- PROLONGATION (Torsades de Pointes)- more common with IV administration
    LIMIT IV DOSE of ONDANSETRON to 16 mg** (lowest risk is w/palonosetron)
  2. SEROTONIN SYNDROME* (when used in combo with other serotonergic agents)
  3. hypersensitivity rxns
30
Q

Q: list corticosteroid drug
Q: contraindications
Q: side effects

A
  1. Dexamethasone (Decadron)*
  2. systemic fungal infections
  3. short-term s/e include INCREASED APPETITE, wt gain, FLUID RETENTION, emotional instability (mood swings, irritability, acute psychosis), INSOMNIA*, Gi upset/dyspepsia
  4. higher doses INCREASE BP AND BLOOD GLUCOSE* (esp in pts w/diabetes)
31
Q

MOA: BZD

ENHANCES GABA* (an inhibitory neurotransmitter), which decreases neuronal excitability and results in the alleviation of anxiety and suppression of ANTICIPATORY N/V*

Q: List BZD drug
Q: when to start

A
  1. Lorazepam (ATIVAN)*
  2. start the EVENING prior to chemotherapy (and day of chemo) if used for anticipatory N/V
32
Q

MOA Dopamine Receptor Antagonist:\

BLOCK DOPAMINE RECEPTORS* in the CNS including the CHEMORECEPTOR TRIGGER ZONE

Q: list drugs

A

Olanzapine (ZYPREXA)*

Prochlorperazine*

Promethazine (Phenergan*, Promethegan)

Metoclopramide (REGLAN)*

Haloperidol (Haldol*)

33
Q

which dopamine RA agent should DECREASE DOSE BY 50% when CrCl is <60

A

Metoclopramide (Reglan)

34
Q

Boxed Warnings for:

Q: Promethazine
Q: Metoclopramide

A
  1. promethazine: do NOT use in kids < 2 yrs of age (risk of respiratory depression)**
    can cause serious TISSUE INJURY due to EXTRAVASATION if administered intra-ARTERIALLY, SC,or IV**
  2. metoclopramide: TARDIVE DYSKINESIA (TD) that can be IRREVERSIBLE* (d/c if s/sxs occur; risk increase with renal impairment)
    do NOT use > 12 weeks*
35
Q

Warnings for Dopamine RAs

A

Avoid use in pts with PARKINSON DISEASE (can EXACERBATE sx’s)

36
Q

S/E of Dopamine RAs

A

SEDATION, LETHARGY, ACUTE EPS (antidote is Benadryl or benztropine)

decrease seizure threshold

strong anticholinergic s/e (constipation) except with metoclopramide (prokinetic effect causing diarrhea)

37
Q

Q: List Cannabinoid drugs
Q: How to store them
Q: s/e

A
  1. DRONABINOL*
    MARINOL* (C III- capsules)
  2. Refrigerate*
  3. SOMNOLENCE, EUPHORIA, INCREASED APPETITE*